Clearside Biomedical ( (CLSD) ) has issued an announcement.
Clearside Biomedical, Inc. announced positive topline results from its Phase 2b ODYSSEY clinical trial for CLS-AX in treating wet AMD, indicating readiness for Phase 3. These results, significant for the multi-billion dollar wet AMD market, show potential for a reduced treatment burden and re-dosing capability, positioning CLS-AX as a competitive therapy. The company leverages proprietary technology for precise drug delivery, aiming to improve patient outcomes while tapping into a growing market need.
See more insights into CLSD stock on TipRanks’ Stock Analysis page.